Beruflich Dokumente
Kultur Dokumente
STATE-OF-THE-ART PAPER
Clinical Characteristics of
Peripartum Cardiomyopathy in the United States
Diagnosis, Prognosis, and Management
Uri Elkayam, MD
Los Angeles, California
Peripartum cardiomyopathy is a pregnancy-associated myocardial disease characterized by the development of
heart failure due to marked left ventricular systolic dysfunction. Although the disease is relatively uncommon, its
incidence is increasing, and it can be associated with important and lasting morbidity and with mortality. Peripartum cardiomyopathy seems to affect women in different parts of the world but with considerable differences in clinical presentation. The purposes of this review are to describe the clinical profile of peripartum
cardiomyopathy in the United States and to provide recommendations for the diagnosis and the management of this disease. (J Am Coll Cardiol 2011;58:65970) 2011 by the American College of Cardiology
Foundation
660
Elkayam
Peripartum Cardiomyopathy
ARB ! angiotensin
receptor blocker
Incidence
Abbreviations
and Acronyms
ACE ! angiotensinconverting enzyme
DCM ! dilated
cardiomyopathy
Figure 1
Red bars represent 23 patients with diagnosis before the last month of pregnancy. Green bars represent 100 patients diagnosed in the last month of pregnancy or the 5-month
postpartum. PP # postpartum; PPCM # peripartum cardiomyopathy. Adapted from Elkayam et al. (8).
Elkayam
Peripartum Cardiomyopathy
661
Incidence
PPCM in the
UnitedinStates
Table 1 of Incidence
of PPCM
the United States
First Author
(Year)
(Ref. #)
Study Design
Age (yrs),
Range (Mean)
Ethnic Background
Period of
Study
Rate
Witlin et al.
(1997) (11)
28 of 67,369 deliveries
2935 (32)
19881994
1 in 2,406
Chapa et al.
(2005) (17)
35 of 40,200 deliveries
1638 (27 $ 6)
19882001
1 in 1,149
Brar et al.
(2006) (19)
Retrospective review,
Southern California Kaiser
Permanente
60 of 241,497 deliveries
33 $ 7
19962005
Mielniczuk
(2006) (18)
NA (29.7)
19902002
1 in 3,189
scription 3 (STAT3) protein (24). Absence of cardiomyocyte STAT3 in the postpartum heart resulted in increased
oxidative stress secondary to blunted induction of the
antioxidant enzyme manganese superoxide dismutase, leading to increased expression and proteolytic activity of cardiac
cathepsin D and resulting in cleavage of the nursing
hormone prolactin into an antiangiogenic and proapoptotic
16-kDa form with a detrimental effect on the myocardial
microvasculature resulting in myocardial hypoxemia and
apoptosis and the development of PPCM. Preliminary data
in human demonstrating a favorable effect of bromocriptine,
a pharmacological inhibitor of prolactin in a limited number
of patients with PPCM, may support this mechanism of
PPCM (25).
Associated Conditions
Strong associations have been shown between PPCM and
older maternal age, history of hypertension, multiple pregnancies, and African American background.
Age. Although the disease has been reported in women
between the ages of 16 and 44 years, the mean age of
women with PPCM in the United States has ranged from
27 to 33 years (8,11,1719) (Table 1), with "60% of
patients reported in 1 study to be "30 years of age (8).
Figure 2
662
Elkayam
Peripartum Cardiomyopathy
Figure 3
Elkayam
Peripartum Cardiomyopathy
Figure 4
663
NA
NA
NA
NA
NA
NA
LVEF
0%
Retrospective, single center
Modi et al. (2009) (58)
15.9%
Retrospective, nationwide
Goland et al. (2009) (30)
54 months
40
35%
6%
7%
49% at 6 months
19 months
60
4.7 yrs
NA
16,296
182
NA
3.2%
NA
NA
NA
LVEDD !5.6 cm, nonAfrican
American race, no LV
thrombus
NA
In hospital total
2.5%
NA
LVEDD !6.0 cm, LVEF "20%
10%
6.5%
9.6%
0%
45%
55
41% at 3 months
NA
43 $ 43 months
32
NA
NA
18%
7%
NA
NA
NA
42
28
Figure 5
8.6 yrs
Mortality
Recovery of LV Function
(LVEF >50%)
Mean Follow-Up
Period
n
Study Design
First Author (Year) (Ref. #)
Outcomes
Patients With
PPCM in
thePPCM
UnitedinStates*
Table 2 ofOutcomes
of Patients
With
the United States*
11%
Predictors of Death
and Transplantation
Predictors of LV Recovery
Elkayam
Peripartum Cardiomyopathy
Heart
Transplantation
664
incidence of these complications are probably due to variations in patient populations, diagnostic criteria, and treatments, as well as reporting bias. Felker et al. (72), in a
retrospective review of cardiomyopathies of various etiologies, reported markedly lower mortality in PPCM compared
with other forms of myocardial disease. At the same time,
however, PPCM has become an increasingly recognized
cause of pregnancy-related maternal mortality (73,74).
Timing and mode of death. Goland et al. (30) provided
detailed information regarding mortality in 13 patients,
most of whom died either suddenly (38%) or of progressive
HF (45%) between the day of delivery and 8 years postpartum. Whitehead et al. (74) reported on 17 cases of death
due to PPCM between 1991 and 1997. Mortality increased
with maternal age, in women with live birth order of !4,
and in black women, who were 6.4 times more likely to die
compared with whites. Eighteen percent of deaths occurred
within 1 week and 87% within 6 months of diagnosis (Fig. 5),
and mortality was due either to progressive HF or to sudden
cardiac death. Mortality was found by Goland et al. (30) to
be higher in women with baseline LVEFs "25% as well as
in women in whom the diagnosis of PPCM was delayed.
Outcome of Subsequent Pregnancy
Habli et al. (75) reported on 21 patients with a mean
LVEF "40% who had subsequent pregnancy, with worsening of HF in 29% and in none of 8 other patients who
terminated their subsequent pregnancies. Two patients with
initial LVEFs !25% (follow-up LVEFs not provided) who
had subsequent pregnancy and 5 of 8 women who terminated their pregnancies demonstrated clinical deterioration
requiring referral for cardiac transplantation.
Modi et al. (58) described 44 indigent patients with
PPCM and reported clinical worsening in 28% of those who
had subsequent pregnancies (number of patients not provided) but no maternal death. Elkayam et al. (76) reported
on the outcomes of 60 subsequent pregnancies in 44
women, 28 after recovery of LV function (group 1) and 16
with LV dysfunction (group 2). Subsequent pregnancies
were associated with reductions in mean LVEF in the total
Elkayam
Peripartum Cardiomyopathy
Figure 6
Red bars represent women with recovered left ventricular (LV) function before
subsequent pregnancy; green bars represent women with persistent LV dysfunction. HF # heart failure; LVEF # left ventricular ejection fraction. Data
derived from Elkayam et al. (76).
665
666
Elkayam
Peripartum Cardiomyopathy
PENTOXIFYLLINE.
Elkayam
Peripartum Cardiomyopathy
667
668
Elkayam
Peripartum Cardiomyopathy
REFERENCES
Elkayam
Peripartum Cardiomyopathy
669
63. Rasmusson K, Alharethi R, Budge D, et al. Peripartum cardiomyopathy: echocardiographic characteristics and medication use in
patients with versus without recovery of left ventricular function.
J Card Fail 2010;16:S86.
64. Napporn AG, Kane A, Damorou JM, et al. Intraventricular thrombosis complicating peripartum idiopathic-myocardiopathy. Ann Cardiol Angeiol 2000;49:309 14.
65. Agunanne E. Peripartum cardiomyopathy presenting with a pulmonary embolism: an unusual case. South Med J 2008;101:646 7.
66. Box LC, Hanak V, Arciniegas JG. Dual coronary emboli in peripartum cardiomyopathy. Tex Heart Inst J 2004;31:442 4.
67. Ibebuogu UN, Thornton JW, Reed GL. An unusual case of peripartum cardiomyopathy manifesting with multiple thrombo-embolic
phenomena. Thromb J 2007:5:18.
68. Jha P, Jha S, Millane TA. Peripartum cardiomyopathy complicated
by pulmonary embolism and pulmonary hypertension. Eur J Obstet
Gynecol Reprod Biol 2005;123:1213.
69. Quinn B, Doyle B, Mclnerney J. Postnatal pre-cordial pain, Pulmonary embolism or peripartum cardiomyopathy. Emerg Med J 2004;
21:746 7.
70. Shimamoto T, Marui A, Oda M, et al. A case of peripartum
cardiomyopathy with recurrent left ventricular apical thrombus. Circ
J 2008;72:853 4.
71. Hellgren M. Hemostasis during normal pregnancy and puerperium.
Semin Thromb Hemost 2003;29:12530.
72. Felker GM, Thompson RE, Hare J, et al. Underlying causes and
long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000;342:1077 84.
73. Lang CT, King JC. Maternal mortality in the United States. Best
Pract Res Clin Obstet Gynaecol 2008;22:51731.
74. Whitehead SJ, Berg CJ, Chang J. Pregnancy-related mortality due to
cardiomyopathy: United States, 19911997. Obstet Gynecol 2003;
102:1326 31.
75. Habli M, OBrien T, Nowack E, Khoury S, Barton JR, Sibai B.
Peripartum cardiomyopathy: prognostic factors for long-term maternal outcome. Am J Obstet Gyenecol 2008;199:415.e15.
76. Elkayam U, Tummala PP, Rao K et al. Maternal and fetal outcomes
of subsequent pregnancies in women with peripartum cardiomyopathy. N Engl J Med 2001;334:156771.
77. Fett JD, Fristoe KL, Welsh SN. Risk of heart failure relapse in
subsequent pregnancy among peripartum cardiomyopathy mothers.
Int J Gynaecol Obstet 2010;109:34 6.
78. Fett J. Personal commentary: monitoring subsequent pregnancy in
recovered peripartum cardiomyopathy mothers. Crit Pathw Cardiol
2010;8:172 4.
79. Elkayam U. Pregnant again after peripartum cardiomyopathy: to be
or not to be? Eur Heart J 2002;23:753 6.
80. Thorne S, MacGregor A, Nelson-Piercy C. Risks of contraception
and pregnancy in heart disease. Heart 2006;92:1520 5.
81. American Academy of Pediatrics. Policy statement: breastfeeding and
the use of human milk. Pediatrics 2005;115:496 506.
82. Lindenfeld J, Albert NM, Boehmer JP, et al. Executive summary:
HFSA 2010 comprehensive heart failure practice guideline. J Card
Fail 2010;16:475539.
83. Briggs GG, Freeman RK, Yatte SJ. Drugs in Pregnancy and
Lactation. 8th edition Philadelphia, PA: Wolters Kluwer, 2008.
84. Shotan A, Widerhorn J, Hurst A, Elkayam U. Risks of angiotensinconverting enzyme inhibition during pregnancy: experimental and
clinical evidence, potential mechanisms and recommendations for
use. Am J Med 1994;96:451 6.
85. Hurst AK, Hoffman K, Frishman WH, Elkayam U. The use of beta
adrenergic blocking agents in pregnancy and lactation. In: Elkayam
U, Gleicher N, editors. Cardiac Problems in Pregnancy. 3rd edition.
New York, NY: Wiley-Liss, 1998:35772.
86. American Academy of Pediatrics, Committee on Drugs. The transfer
of drugs and other chemicals into human milk. Pediatrics 2001;108:
776 89.
87. Bozkurt B, Villaneuva FS, Holubkov R, et al. Intravenous immune
globulin in the therapy of peripartum cardiomyopathy. J Am Coll
Cardiol 1999;34:177 80.
88. Sliwa K, Skudicky D, Candy G, Bergemann A, Hopley M, Sareli P.
The addition of Pentoxifylline to conventional therapy improves
outcome in patients with peripartum cardiomyopathy. Eur J Heart
Fail 2002;4:3059.
670
Elkayam
Peripartum Cardiomyopathy
99.
100.
101.
102.
103.
104.
105.
106.
107.